ClinicalTrials.gg
RecruitingNCT07504120MSUpdated Oct 6, 2026

The Effect of Remotely Delivered Pilates on Physical , and Psychological Outcomes in Individuals With Multiple Sclerosis

An interventional study of Pilates in Multiple Sclerosis, Pilates Exercise and Walking, sponsored by University of Illinois at Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 6, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Multiple Sclerosis by University of Illinois at Chicago — 6 open to participants now, 9 under way, none of them phase 3. Multiple Sclerosis · University of Illinois at Chicago.

Planned enrollment
10th of 15
50 · median 52
Started
2025
with 2 others
No phase
14 of 15
6 open now
Registered
13th of 15
by date

Among the 15 studies in Multiple Sclerosis by University of Illinois at Chicago, this one is the 10th largest by planned enrollment, is one of 3 that started in 2025, is one of 14 with no phase, and was the 13th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

6 of the 15 studies in Multiple Sclerosis by University of Illinois at Chicago are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Multiple Sclerosis by University of Illinois at Chicago, or all of them as a file.
02

Study summary

Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.

Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.

Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression \& anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Read the detailed description

The current study will determine the feasibility and efficacy of a 16-week remotely delivered Pilates intervention for improving physical and psychological outcomes, and QOL, compared with a control condition, in individuals with MS. This represents a significant step forward in examining Pilates as an accessible, complementary therapy in MS.

03

Conditions studied

  • Multiple Sclerosis
  • Pilates Exercise
  • Walking
  • Balance
  • Fatigue in Multiple Sclerosis
  • Pain Management
  • Quality of Life
  • Depression
  • Cognition
  • Fatigue

Keywords

  • multiple sclerosis
  • Pilates
  • Fatigue
  • Cognition
  • Quality of life
  • Walking
  • Depression
  • Balance
  • Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Self-reported diagnosis of multiple sclerosis by a neurologist
  • Relapse-free for the past 30 days before screening
  • Able to speak and read English as the primary language
  • Access to the internet and e-mail,
  • Ability to use Zoom, and willingness to complete testing sessions and questionnaires
  • Ambulatory without an assistive device (for example, cane)
  • Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS)
  • Insufficiently active, defined as a score \< 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS)
  • Adequate visual ability and literacy to read materials printed in 14-point font
  • Currently treated with a disease-modifying therapy

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Elevated risk for strenuous or maximal exercise, defined as more than one "Yes" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Other
    Pilates group

    Behavioral: Pilates group

    Behavioral: Pilates

  • No intervention
    Control group

    Waitlist Group

Interventions

  • BehavioralPilates

    REMOTLY PILATES EXERCISE

06

What researchers measure

Primary outcomes

  1. Change from baseline in walking endurance (Six-Minute Walk Test distance)

    Distance walked during the Six-Minute Walk Test (6MWT) will be measured in meters. The outcome is the change from baseline to 16 weeks in 6MWT distance.

    Time frame: Baseline and 16 weeks (end of treatment)

  2. Change from baseline in walking speed (Timed 25-Foot Walk)

    Walking speed will be assessed using the Timed 25-Foot Walk (T25FW). The outcome is the change from baseline to 16 weeks in time to walk 25 feet, measured in seconds.

    Time frame: Baseline and 16 weeks (end of treatment)

  3. Change from baseline in balance (Berg Balance Scale)

    Balance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, and the outcome will be the change from baseline to 16 weeks in the BBS total score (range 0-56), with higher scores indicating better balance and lower risk of falls.

    Time frame: Baseline and 16 weeks (end of treatment)

  4. Change from baseline in fatigue (Fatigue Severity Scale)

    Fatigue will be measured using the Fatigue Severity Scale (FSS), a 9-item questionnaire assessing the impact of fatigue on daily functioning. Each item is rated from 1 to 7, and the outcome will be the change from baseline to 16 weeks in the FSS mean score (range 1-7), with higher scores indicating more severe fatigue.

    Time frame: Baseline and 16 weeks (end of treatment)

  5. Change from baseline in pain (Short-form McGill Pain Questionnaire)

    Pain will be measured using the Short-form McGill Pain Questionnaire (SF-MPQ). The outcome is the change from baseline to 16 weeks in SF-MPQ total score.

    Time frame: Baseline and 16 weeks (end of treatment)

Secondary outcomes

  1. Change from baseline in cognitive processing speed (Symbol Digit Modalities Test)

    Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). The outcome is the change from baseline to 16 weeks in SDMT total score, with higher scores indicating better processing speed. SDMT scores typically range from 0 to about 110 correct responses.

    Time frame: Baseline and 16 weeks (end of treatment)

  2. Change from baseline in verbal learning and memory (California Verbal Learning Test-II)

    Verbal learning and memory will be assessed using the California Verbal Learning Test-II (CVLT-II). The outcome is the change from baseline to 16 weeks in CVLT-II total recall score, with higher scores indicating better verbal learning and memory. CVLT-II total recall scores typically range from 0 to about 80.

    Time frame: Baseline and 16 weeks (end of treatment)

  3. Change from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised)

    Visuospatial learning and memory will be assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). The outcome is the change from baseline to 16 weeks in BVMT-R total recall score, with higher scores indicating better visuospatial memory. BVMT-R total recall scores typically range from 0 to 36.

    Time frame: Baseline and 16 weeks (end of treatment)

  4. Change from baseline in depression symptoms

    Depression will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Depression subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in depression total score, with higher scores indicating greater depressive symptoms. Typical depression scales have ranges such as 0-21 (HADS-D) ; enter the exact range that matches the scale you are using.

    Time frame: Baseline and 16 weeks (end of treatment)

  5. Change from baseline in anxiety symptoms

    Anxiety will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Anxiety subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in anxiety total score, with higher scores indicating greater anxiety. Typical anxiety scales have ranges such as 0-21 (HADS-A) or 0-63 (BAI); enter the exact range that matches the scale you are using.

    Time frame: Baseline and 16 weeks (end of treatment)

  6. Change from baseline in health-related quality of life

    Health-related quality of life will be assessed using a validated questionnaire (e.g., the MSQoL-54 or a comparable instrument). The outcome is the change from baseline to 16 weeks in the quality-of-life total score or composite score. For instruments scored 0-100, higher scores typically indicate better quality of life; specify the exact scoring range and direction according to your chosen measure.

    Time frame: Baseline and 16 weeks (end of treatment)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 25 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Jun 2026 → Nov 2025 and primary completion Nov 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Mar 31, 2026
StartActual
Nov 1, 2025was Jun 2026
Primary completionEst.
Dec 1, 2027was Nov 2027
CompletionEst.
Dec 1, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 6, 2026
Sites
1 site added — first site in United States
Show site
  • University of Illinois Chicago · Chicago, United States
Oct 6, 2026
Start date
Jun 1, 2026→Nov 1, 2025 (actual)
Oct 6, 2026
Primary completion
Nov 1, 2027→Dec 1, 2027
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • University of Illinois Chicago · Chicago, United States
    Start date Jun 1, 2026→Nov 1, 2025 (now actual)
    Primary completion Nov 1, 2027→Dec 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07504120
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Nov 1, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion